CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock ...

In July 2024, Moderna was awarded $176 million from the US government to advance the development of its mRNA H5N1 (bird flu) vaccine, which is in the early stages of testing. The award came after an ...

Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains ...

Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.

On Monday, the U.S. Centers for Disease Control and Prevention (“CDC”) reported the first human death in the country from the H5N1 virus, also known as bird flu. Despite the death, CDC believes that ...

Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first ...

Moderna surged as investors turned eyed potential demand for a vaccine to protect against bird flu after the US reported its ...

Jefferies sees Arbutus (ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE)/GSK ...

Novavax (NASDAQ:NVAX), and other vaccine developers extended recent gains on Tuesday as investors reacted to rising flu and ...